Intelligent Surgical Lasers
This article was originally published in The Gray Sheet
Executive Summary
Gearing up for Phase I clinical trial of its Eye Laser System for intrastromal ablation to correct nearsightedness, following the receipt of investigational device exemption (IDE) approval from FDA. Slated to begin in the first quarter of 1994, the study will be conducted on 10 patients at the New York Eye and Ear Infirmary and the Anheuser-Busch Eye Institute in St. Louis. ISL says its intrastromal photorefractive keratectomy procedure (ISPRK) is designed to be less invasive than radial keratotomy or photorefractive keratectomy. The company is planning to file additional IDEs to use ISPRK in treating hyperopia and astigmatism
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.